Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Background and Purpose- The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5-1.2) mmol/L and significantly reduced major vascular events in the FOURIER trial (Further Cardiovascular Outcomes Rese...

Full description

Bibliographic Details

Published in:	Stroke (1970) Vol. 51; no. 5; p. 1546
Main Authors:	Giugliano, Robert P, Pedersen, Terje R, Saver, Jeffrey L, Sever, Peter S, Keech, Anthony C, Bohula, Erin A, Murphy, Sabina A, Wasserman, Scott M, Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S
Format:	Journal Article
Language:	English
Published:	United States 01.05.2020
Subjects:	peripheral arterial disease C-reactive protein stroke evolocumab proprotein convertase 9
ISSN:	1524-4628, 1524-4628
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!